LEADER 03933nam 2200925z- 450 001 9910557484703321 005 20231214133524.0 035 $a(CKB)5400000000042985 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69300 035 $a(EXLCZ)995400000000042985 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aGenomics and Models of Nerve Sheath Tumors 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (172 p.) 311 $a3-03943-489-6 311 $a3-03943-490-X 330 $aNerve sheath tumors can be a significant cause of morbidity for many patients. These include benign tumors such as schwannomas, diffuse and plexiform neurofibromas, and atypical neurofibromas, as well as the aggressive soft tissue sarcoma known as the malignant peripheral nerve sheath tumor (MPNST). Nerve sheath tumors occur sporadically and in the context of the clinical neuro-genetic tumor predisposition syndromes neurofibromatosis type 1 (NF1) and type 2 (NF2). Historically, the mainstay of treatment for nerve sheath tumors has been surgery. However, for both benign and malignant nerve sheath tumors, there is a high recurrence rate, highlighting the pressing need for novel therapies. As we have entered the genomic era, the hope is that an improved understanding of the genetics, and therefore the biology, of these tumors will ultimately lead to therapies that result in better outcomes. In this Special Issue, we include both review articles and original research related to the genomic understanding and modeling of schwannomas, plexiform and diffuse neurofibromas, atypical neurofibromas, and malignant peripheral nerve sheath tumors as well as genomic methods?being developed and applied to advance our?understanding of?these tumors. 606 $aMedicine$2bicssc 610 $aneurofibromatosis type 1 610 $anerve sheath tumor 610 $acancer 610 $alatent variables 610 $amachine learning 610 $asupervised learning 610 $atransfer learning 610 $arandom forest 610 $ametaVIPER 610 $atumor deconvolution 610 $aneurofibromatosis 610 $amalignant peripheral nerve sheath tumor 610 $aMPNST 610 $apolycomb repressive complex 610 $aPRC2 610 $aNF1 610 $akinase 610 $akinome adaptation 610 $akinome reprogramming 610 $aMET 610 $aMEK 610 $adoxorubicin 610 $acapmatinib 610 $atram 610 $agenomics 610 $atumor evolution 610 $apathology 610 $anext generation sequencing 610 $aclinical genetics 610 $amalignant peripheral nerve sheath tumors 610 $aplexiform neurofibromas 610 $aSchwann cells 610 $aneurofibromatosis type 1 syndrome 610 $aneurofibromin 1 610 $agenetically engineered mouse models 610 $aheterogeneity 610 $aCRISPR/Cas9 610 $amouse models 610 $asarcoma 610 $atumor microenvironment 610 $aneurofibromatosis 1 (NF1) 610 $amebendazole (MBZ) 610 $aCOX-2 inhibitor 610 $amalignancy 610 $achemoprevention 610 $anerve sheath tumors 615 7$aMedicine 700 $aHirbe$b Angela C$4edt$01312695 702 $aPratilas$b Christine A$4edt 702 $aDodd$b Rebecca D$4edt 702 $aHirbe$b Angela C$4oth 702 $aPratilas$b Christine A$4oth 702 $aDodd$b Rebecca D$4oth 906 $aBOOK 912 $a9910557484703321 996 $aGenomics and Models of Nerve Sheath Tumors$93030922 997 $aUNINA